Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of four-drug fixed-dose antituberculosis combination versus separate formulations in healthy Chinese volunteers
ChiCTR-TTRCC-12002451Phase 4Completed
- Sponsor
- Beijing Tuberculosis and Thoracic Tumor Research Institute
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifampicin, isoniazid, ethambutol and pyrazinamide in Tuberculosis (TB) (2 arms), sponsored by Beijing Tuberculosis and Thoracic Tumor Research Institute. Primary endpoints: AUC(0-24) and Cmax. Started Nov 2011; status: completed.
02
Drugs
rifampicinisoniazidethambutolpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR-TTRCC-12002451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TTRCC-12002451.